Applied Therapeutics, Inc. APLT
At closeJul 2, 2026, 4:00 PM EDT
After hours · Jul 2, 4:00 PM ET
- YTD
- +3.00%
- 1 year
- -81.62%
- Market cap
- 99.09M
- Revenue (ttm)
- -212.00K
- EPS (ttm)
- -1.42
- Shares out
- 116.36M
- Forward P/E
- -1.85
- YTD return
- +3.00%
- 1-year return
- -81.62%
- Avg volume
- 5.16M
- Open
- 0.103
- Previous close
- 0.103
- Day's range
- 0.103 – 0.103
- 52-week range
- 0.78 – 10.62
- Beta
- 2.02
- Analysts
- Buy
- Price target
- 5.92 (+5644.3%)
- Earnings date
- Aug 7, 2024
2Y -9.6370 (-98.94%)
Key statistics
- Enterprise value
- 5.51M
- PEG ratio
- 0.00
- Price / sales
- -467.40
- Price / book
- 16.70
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -3.58M
- Total cash
- 98.87M
- Total debt
- 1.97M
- Return on equity
- 0.00%
- Short % of float
- 13.60%
- 50-day average
- 6.47
- 200-day average
- 5.81
Analyst view
Consensus: buy
- Target (low)
- 1.50
- Target (mean)
- 5.92
- Target (high)
- 13.00
- Strong buy0
- Buy3
- Hold3
- Sell0
- Strong sell0
Next earnings
Aug 7, 2024
Expected Aug 7, 2024. Consensus EPS estimate -0.19413.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.13 | -0.20 | -0.07 | -53.85% |
| Aug 7, 2024 | Jun 1, 2024 | -0.10 | -0.13 | -0.03 | -30.00% |
| Aug 7, 2024 | Jun 1, 2024 | -0.10 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | -0.07 | -0.16 | -0.09 | -128.57% |
| May 9, 2024 | Mar 1, 2024 | -0.07 | — | — | — |
| Mar 6, 2024 | Dec 1, 2023 | -0.15 | -0.33 | -0.18 | -120.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 23, 2024 | William Blair | down | Outperform | Market Perform |
| Dec 20, 2024 | RBC Capital | main | Sector Perform | Sector Perform |
| Dec 2, 2024 | UBS | down | Buy | Neutral |
| Nov 29, 2024 | Citigroup | main | Buy | Buy |
| Nov 29, 2024 | Baird | main | Outperform | Outperform |
| Nov 29, 2024 | RBC Capital | down | Outperform | Sector Perform |
About Applied Therapeutics, Inc.
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- appliedtherapeutics.com
News
Why RF Industries Shares Are Trading Higher By 21%; Here Are 20 Stocks Moving Premarket 
S&P 500 Down 1%; Broadcom Earnings Top Views 
12 Health Care Stocks Moving In Friday's Intraday Session 
Dow Rises Over 100 Points; Lululemon Posts Upbeat Q3 Earnings 
12 Health Care Stocks Moving In Friday's Pre-Market Session 
Why Lululemon Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket 
12 Health Care Stocks Moving In Monday's Intraday Session - 12 Health Care Stocks Moving In Monday's Pre-Market Session
- 12 Health Care Stocks Moving In Friday's After-Market Session
- 12 Health Care Stocks Moving In Thursday's After-Market Session
Your note
Sign in to keep a note on APLT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALEXANDRIA REAL ESTATE EQUITIES INC | Beneficial Owner of more than 10% of a Class of Security | Sale | Jun 4, 2024 | 0 |
| FUNTLEYDER LESLIE D | Chief Executive Officer | Stock Award(Grant) | Dec 18, 2024 | 427,911 |
| HOOKS CORWIN DALE | Officer | Stock Award(Grant) | Apr 11, 2024 | 300,000 |
| JOHNSON JOHN H. | Officer and Director | Stock Award(Grant) | Dec 18, 2024 | 500,000 |
| KANTER STACY J | Director | Stock Award(Grant) | Jun 5, 2024 | 108,000 |
| LERNER TEENA L. PH.D. | Director | Stock Award(Grant) | Jun 5, 2024 | 105,422 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Janus Henderson Group PLC | 9.06% | 10,541,528 | 8.98M | Sep 29, 2024 |
| Morgan Stanley | 8.51% | 9,904,530 | 8.43M | Sep 29, 2024 |
| VR Adviser, LLC | 8.44% | 9,825,000 | 8.37M | Sep 29, 2024 |
| Perceptive Advisors Llc | 6.88% | 8,005,000 | 6.82M | Sep 29, 2024 |
| Blackrock Inc. | 5.97% | 6,942,699 | 5.91M | Sep 29, 2024 |
| Franklin Resources, Inc. | 5.84% | 6,800,910 | 5.79M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Franklin Strategic Series-Franklin Biotechnology Discove | 2.97% | 3,450,500 | 2.94M | Jul 30, 2024 |
| Vanguard Total Stock Market Index Fund | 2.71% | 3,153,938 | 2.69M | Sep 29, 2024 |
| Simplify Exchange Traded Fds-Simplify Propel Opportunities ETF | 2.42% | 2,817,505 | 2.40M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.14% | 2,486,153 | 2.12M | Oct 30, 2024 |
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 1.57% | 1,830,616 | 1.56M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.99% | 1,151,026 | 980.21K | Sep 29, 2024 |